Key result
rhGH therapy increases ventricular mass, stroke volume, and cardiac output in growth hormone-deficient patients.
Why the study?
The effects of recombinant human growth hormone therapy on cardiac function in patients with growth hormone deficiency and cardiac failure were not fully understood.
Does recombinant human growth hormone therapy improve cardiac function in patients with growth hormone deficiency or cardiac failure?
Does recombinant human growth hormone therapy improve cardiac function in patients with growth hormone deficiency or cardiac failure?
Growth hormone appears necessary for maintaining normal cardiac function, and its replacement may improve cardiac parameters in deficient patients.
No takes yet. Share an insight, caveat, or question.
May support GH replacement to augment cardiac output in GHD; leaves open outcome benefits and efficacy in heart failure.
Ross C. Cuneo (2001) conducted a review in Cardiac failure and growth hormone deficiency. Recombinant human growth hormone (rhGH) vs. Placebo was evaluated. Recombinant human growth hormone therapy for up to 6 months increases ventricular muscle mass, stroke volume, and cardiac output in patients with growth hormone deficiency.